Market Backdrop: A Year Like No Other for Portfolios
When the year began, investors hoped for the familiar balance of growth and stability. By the time the calendar flipped to 2023, it was clear that 2022 would be remembered for a rapid shift in policy, stubborn inflation, and a broad re-pricing of risk. The S&P 500 closed the year down roughly 19%, a slide that reverberated through both stocks and bonds as the Federal Reserve tightened monetary policy to tame price gains. In that environment, many investors assumed every corner of the market would move in lockstep downward or recover in sync—the very dynamic that tests a portfolio’s diversification.
Among the assets proving unexpectedly durable was a healthcare sector exchange-traded fund. The health care complex—pharmaceuticals, medical devices, and hospitals—tends to show inelastic demand in the face of a downturn, providing a cushion when the broad market sprints into volatility. In practice, the Health Care Select Sector SPDR Fund (XLV) drew attention not because it shot higher, but because it demonstrated a steadier path through the storm. This is where the narrative of when 2022 tore through the markets gains traction: a defensive tilt that might feel modest in a bull market but can matter a lot when risk assets retreat.
What XLV Is and Why It Stood Out
XLV tracks the Health Care Select Sector Index, a basket of large-cap healthcare names that are widely represented in retirement accounts and tax-advantaged plans. The fund’s emphasis on health care equipment, services, and medicines tends to produce steadier earnings than more cyclical sectors. It’s not immune to pullbacks, but the drawdowns typically run shallower and the recoveries can come more quickly because demand for healthcare remains relatively sticky even when households cut back elsewhere.
Industry observers point to several structural factors that make XLV resilient during a downturn. First, healthcare demand relies on necessities—think medicines, doctors’ visits, and hospital care—rather than discretionary spending. Second, many healthcare companies carry robust free-cash-flow profiles and reasonable pricing power, even when the economy slows. Third, the sector’s revenue mix often includes a strong dose of government or payer support, which can cushion earnings during weak macro cycles. Taken together, these dynamics explain why XLV often behaves as a defensive anchor in a risk-off phase.
One portfolio strategist summarized the case this way: “When the market gets volatile, investors gravitate toward what feels like a soft landing asset. Healthcare is that kind of ballast because the demand is less tied to the business cycle.”
Historical Signal: How XLV Has Weathered Downturns
Long-run data show XLV’s approach to risk has a lower beta than the broad market, meaning it tends to move less in tandem with the S&P 500. Over extended periods, XLV has delivered returns similar to broad-market peers like SPY while registering smaller losses during bear phases. For investors seeking a ballast against equity volatility, the ETF’s history offers a cautious but meaningful signal: tilt toward defensive sectors can reduce portfolio risk without relying on exotic hedges.
In the 2022 bear market, the resilience of XLV relative to the broader market was pronounced enough to prompt fresh questions about why many retirements accounts still underweight the sector. The converse observation is equally important: those same accounts that avoided healthcare tilts often missed a corridor of protection that could have improved risk-adjusted outcomes in a rough year. As one veteran analyst noted, “The data suggest defensive exposure has a structural role, but it’s not a default stance for DIY investors.”
Why Aren’t More Retirement Accounts Tilted Toward XLV?
Despite its defensive profile, XLV remains a relatively modest component in many retirement plans. There are several practical reasons for this split in approach:
- Asset-allocation discipline: Many retirement portfolios aim for broad diversification with a bias toward low-cost, market-cap-weighted funds. Sector ETFs like XLV—while offering protection—can disrupt the simplicity of core holdings that investors rely on for long-run growth.
- Rethinking risk in retirement transitions: In retirement, risk budgets shift. Savers who prioritize capital preservation tend to favor broad, diversified exposures over sector bets, especially after years of noise around healthcare policy and drug pricing.
- Tax and tax-advantaged accounts: Some investors worry about concentration risk within tax-advantaged accounts that aren’t designed for tactical tilts. Sector bets can complicate rebalancing and tax planning, which many retirement plans emphasize to simplify withdrawals later in life.
- User accessibility and cost: Even with a reasonable expense ratio (XLV’s costs run around 0.12%), the perception of “adding risk” by layering sector exposure can trump the actual risk profile for some savers who prefer a single, broad-market sleeve.
Industry voices emphasize that the question isn’t whether XLV is good or bad for retirement accounts, but whether a given investor’s risk tolerance, time horizon, and withdrawal plan align with a tilt into healthcare. “It’s not about chasing the outperformer of a single year,” said a senior analyst at a wealth-management shop. “It’s about whether a patient, diversified allocation can help weather the next downcycle.”
What This Means for Investors Right Now
As markets have entered a calmer phase in 2024 and 2025, the question for savers shifts from survival to structure. Inflation has cooled, rate expectations have evolved, and many households are rethinking their longevity of funds. In that context, a healthcare tilt can be a rational piece of a broader strategy, particularly for those who want a defensive option without stepping into complicated hedges or expensive overlaid strategies.
One practical takeaway is to reassess the role of XLV in a portfolio that currently relies on broad-market ETFs and a handful of fixed-income slugs. A modest addition—say, 5% to 10% of a core equity sleeve—can deliver defensiveness without sacrificing growth potential in a recovering economy. The key is to rebalance periodically and stay mindful of sector concentration that can creep up over time.
Expert Voices: How Professionals See XLV Today
Market veterans stress that the past decade’s low-interest-rate environment has already reshaped how households think about risk budgeting. As rates move higher or lower in response to inflation trends, the appeal of ETFs like XLV endures because they offer transparent exposure to a well-defined sector with historically stable earnings trajectories.
“The question isn’t whether XLV outperforms the market on a given day,” said Maria Chen, chief investment officer at Crestline Wealth. “The real question is: does adding healthcare exposure reduce the probability of a gut-wrenching drawdown while keeping you on track for a long-run retirement goal? For some investors, the answer is yes.”
Another analyst adds that the real world constraint is also about ease of implementation: “People want simple, predictable building blocks for retirement. XLV isn’t a magic hedge, but it’s a clean, transparent way to introduce defensiveness without complex instruments.”
Takeaways for Savers in 2026 and Beyond
- Revisit core and satellite allocations: Consider a small healthcare sleeve as a defensive ballast within a diversified portfolio, especially in a late-cycle environment where growth stocks are sensitive to policy changes and rate moves.
- Keep costs visible: XLV’s expense ratio is relatively modest, but the impact compounds over time. Ensure total portfolio costs stay in check when evaluating sector tilts.
- Stay disciplined on rebalancing: Sector exposures can drift. A periodic rebalance can preserve intended risk levels and ensure that a defensive tilt continues to serve its purpose when markets swing again.
- Watch policy and demographic shifts: Demographics and healthcare policy shape this sector’s earnings trajectory. A global swing in healthcare demand could reinforce XLV’s defensive traits at times when traditional defensives like bonds falter.
For readers scanning the current market landscape, the enduring lesson remains active, not reactive: the moment when when 2022 tore through the market highlighted the value of thoughtful defensive positioning. It wasn’t about chasing a single year’s winner, but about crafting a portfolio that could endure a spectrum of shocks while staying on track for long-term goals. In that sense, XLV’s hard-won reputation as a steadier sleeve endures as a tangible argument for selective defense in retirement planning.
Bottom Line: A Quiet Edge Worth Measuring
Healthcare ETFs like XLV remind investors that resilience in a bad year does not have to translate into a loud outperformance. Instead, it can translate into steadier year-end numbers and a smoother ride through volatility—an outcome that matters a lot to retirees who cannot tolerate large drawdowns. As markets evolve through 2026, the strategy of combining broad exposure with targeted defensives may continue to be a credible route for investors seeking better risk-adjusted outcomes without overcomplicating their retirement plans.
Discussion